Why Your Medical Building Hasn't Sold: The Overpricing Problem in Healthcare Real Estate Brokerage

A physician reaches out to a commercial broker about selling their medical office building. The broker pitches an aggressive valuation — well above what the physician expected — wins the listing, and puts the property on the market. Six months pass. Then twelve. Then eighteen. The building sits. The physician grows frustrated. The broker recalibrates expectations downward. Eventually the listing either expires, closes at a fraction of the original promise, or the physician walks away having wasted the better part of two years.

This pattern is playing out across the healthcare real estate market right now with troubling frequency. And with the 10-year Treasury moving aggressively upward, it is getting worse. Physicians who don't understand why it happens — and how to spot it before signing an engagement letter — are at serious risk of wasting one of the most valuable windows in their professional lives.

The Root Cause: Negative Leverage

To understand why properties are being overpriced and why those listings stall, you first need to understand negative leverage — the dynamic that is quietly breaking healthcare real estate deals right now.

When a buyer finances a medical office building acquisition, they compare two numbers: the cap rate (the yield the property generates based on its NOI and purchase price) and their borrowing cost (the interest rate on the acquisition loan). When the cap rate exceeds the borrowing cost, the buyer is in positive leverage — debt makes the deal work better. When the cap rate is below the borrowing cost, the buyer is in negative leverage — debt actually destroys returns.

With the 10-year Treasury elevated and commercial real estate lending rates tracking accordingly, many institutional buyers are now looking at borrowing costs in the 6.0–7.0% range. If a medical office building is priced to a 5.5% cap rate, a leveraged buyer is immediately in negative leverage territory. The only buyers who can make that math work are all-cash buyers — a much smaller pool, and one that commands a price discount in exchange for the certainty of cash.

The practical consequence: properties priced to cap rates that made sense in the 2020–2022 zero-rate environment simply do not trade in today's market. Buyers aren't being difficult — the arithmetic doesn't work. No amount of marketing, broker relationships, or time on market changes that fundamental reality.

How the Overpricing Cycle Works

Understanding why brokers overprice requires understanding how brokers win listings. In a competitive pitching environment, the broker who promises the highest number wins the engagement. The physician hears three presentations, selects the broker promising $8M over the ones promising $6.5M, and the listing is signed.

What happens next follows a predictable pattern:

Phase 1: The Launch (Months 1–3)

The property goes to market at the aggressive price. The broker sends it to their buyer database, holds a call for offers, and waits. Offers either don't come, or the offers that do come are well below the asking price. The broker tells the physician that buyers are "still underwriting" or that "the right buyer hasn't seen it yet."

Phase 2: The Rationalization (Months 4–8)

With no deal materializing, the broker begins explaining that "market conditions have shifted" or that interest rates have moved. These explanations are accurate — but they were predictable before the listing was taken. The physician begins to suspect something is wrong but has now invested months in the process and is reluctant to start over.

Phase 3: The Recalibration (Months 9–18)

The broker recommends a price reduction. By this point, the property has been sitting on the market long enough that sophisticated buyers are asking questions — why hasn't it sold? What's wrong with it? Days on market becomes a liability. The property that might have sold quickly at a realistic price now faces buyer skepticism that didn't exist at launch.

Phase 4: The Resolution (or Expiration)

Eventually the property either sells at a price close to what a realistic broker would have promised at the outset, expires without a transaction, or the physician fires the broker and starts over — now with a stigmatized listing history that follows the property to its next marketing effort.

The physician ends up in roughly the same place they would have been with honest pricing from the beginning — minus 12 to 18 months of their life, significant emotional energy, and in many cases a worse outcome due to the days-on-market stigma.

The Tell: Listings vs. Closings

The most reliable way to evaluate whether a broker is pricing honestly is to compare their active listings to their closed transactions. These are two very different things.

Active listings represent what a broker has promised to sell. Closed transactions represent what they have actually delivered. A broker with a large number of active listings and a thin closed transaction record is showing you the gap between what they promise and what they produce.

When you evaluate a broker, ask to see:

• Their closed transaction history for the past 24 months — not their total career volume, not their team's volume, not a parent company's volume. Their closed deals in recent market conditions.
• The ratio of listings taken to listings closed — a broker who takes 20 listings and closes 8 is telling you something very different from a broker who takes 12 listings and closes 11.
• Average days on market for their closed transactions — if their deals are taking 18 months to close, that's not a track record, that's a warning.
• The list price versus closing price on recent deals — if they consistently close at 80–85% of list price, the list price was the fiction, not the market.

A broker who prices honestly will have a high listing-to-closing conversion rate and relatively tight list-to-close price ratios. Their active listing count will be manageable because they're not stockpiling engagements they can't close. Their closed transaction page will be more impressive than their active listings page — not the other way around.

Why the Current Rate Environment Makes This Worse

The 10-year Treasury has moved dramatically over the past 18 months. For healthcare real estate brokers who are still pitching valuations based on cap rates from 2021 or 2022, the math has fundamentally broken down.

In 2021, a physician could sell a medical office building at a 5.5% cap rate and institutional buyers could finance the acquisition with debt at 3.5–4.0%. Positive leverage, strong buyer pool, competitive bidding, quick closings.

In today's environment, that same property at a 5.5% cap rate faces buyers whose debt costs are 6.0–6.5%. The deal is structurally impaired for any leveraged buyer. The only path to closing at a 5.5% cap rate is an all-cash buyer — and all-cash buyers know their value in this market. They price it in.

Brokers who are pitching 2021-era cap rates in 2026 are either unaware of this dynamic or are choosing to ignore it to win the listing. Neither is acceptable when you are relying on them to manage the most significant financial transaction of your professional career.

The honest conversation with a physician today acknowledges where cap rates actually trade, explains the negative leverage dynamic, and presents a realistic price that a real buyer with real debt can underwrite today — not a hypothetical price from a market that no longer exists.

What Realistic Pricing Actually Looks Like in 2026

Realistic pricing for physician-owned medical real estate in 2026 depends on asset profile, lease structure, tenant credit, and market. According to CBRE's Q2 2026 U.S. MOB Market Report, the average MOB cap rate stands at 7.1% — up 4 basis points year-over-year — reflecting a market that has repriced meaningfully from the 5.5–6.0% era of 2020–2022. But as a general framework by asset quality:

• Well-leased MOB, credit tenant, 10+ year NNN, primary market: 6.0–6.75% cap rate
• Physician-owned MOB, strong lease, secondary market: 6.75–7.5% cap rate
• Shorter lease, smaller market, or value-add: 7.5–8.5% cap rate
• ASC, credit operator, 12+ year NNN: 5.5–7.0% cap rate

A broker pricing your property below these ranges — particularly below 6.0% on anything other than an on-campus health system asset — is making a promise the market will not keep. Ask them to show you three comparable closed transactions in the past 12 months that support their cap rate guidance. If they can't produce them, the number is aspirational, not analytical.

The Right Questions to Ask Before Signing an Engagement

Before signing an exclusive listing agreement with any healthcare real estate broker, ask these questions directly:

1. "What cap rate are you pricing this property to, and can you show me three comparable closed transactions in the past 12 months that support it?" — If they can't, the price is unsupported.
2. "How many active listings do you currently have, and how many of those have been on the market for more than 6 months?" — A large backlog of stale listings is a red flag.
3. "What is your list-price-to-close-price ratio on deals you've closed in the past 24 months?" — Anything below 90% suggests a persistent pricing problem.
4. "What happens if we receive no qualified offers in the first 90 days?" — Their answer tells you a lot about their confidence in their own pricing.
5. "Can you explain the negative leverage dynamic and how it affects the buyer pool at your suggested price?" — A broker who can't answer this question in plain language doesn't understand today's market.
6. "How many healthcare real estate transactions did your team close in the past 12 months — specifically?" — Not career volume. Not company volume. Theirs, recent.

What Honest Representation Looks Like

An honest healthcare real estate broker brings you a valuation supported by actual comparable sales data. They explain exactly who the buyers are for your asset and what those buyers can underwrite based on current debt costs. They tell you the realistic range of outcomes — not just the optimistic one — and they back their pricing with a track record of closings, not a catalog of listings.

When CREG takes a listing, we take it because we believe we can close it at the price we've promised. Our business model depends on completed transactions — not listings. We get paid when we close deals, not when we sign engagement letters. That alignment of incentives matters.

We have also seen enough of the overpricing cycle — from the other side of the table, representing buyers — to know exactly what it costs physicians. The time lost. The stigma acquired. The eventual price reduction that lands them where honest pricing would have started. It's avoidable, and we'd rather have the hard conversation upfront than the easy one that leads nowhere.

If Your Building Is Already Stalled

If you have an active listing that has been on the market for more than 90 days without a serious offer, it is worth asking hard questions now rather than later:

• Has the broker provided you with written feedback from the buyers they've shown the property to?
• Have they proposed a price adjustment with supporting comparable data, or have they continued to promise that "the right buyer is coming"?
• Are you seeing evidence of active marketing — new buyer outreach, updated materials, fresh calls for offers — or has the listing gone quiet?

If the answers to these questions concern you, you have options. Listing agreements expire. Brokers can be changed. And a fresh, honestly priced marketing effort — even if it means acknowledging the previous list price was too high — will almost always outperform another six months of wishful thinking.

CREG offers confidential second opinions for physician-owners who want an independent assessment of where their property actually trades in today's market. No obligation. No engagement required.